Youzhao X. Ma
No. 127, Dongming Road
Zhengzhou, 450000, China
Zhengzhou, 450000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Treatment with interferon α-1b, interleukin-2, and thalidomide for persistent RUNX1::RUNX1T1 in a patient with KIT-mutated acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 17, 2025
Changes in HER2, ER, PR, and Ki-67 in HER2-Negative Breast Cancer After Neoadjuvant Chemotherapy: A Case-Control Study.
Journal: Current oncology (Toronto, Ont.)
Published: October 25, 2025
Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: July 07, 2025
Prognostic significance of HER2-low and HER2-zero status before and after neoadjuvant chemotherapy in patients with HER2-negative breast cancer.
Journal: Therapeutic advances in medical oncology
Published: May 05, 2025
Venetoclax-based regimen for the treatment of mixed phenotype acute leukemia: a case report
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: January 02, 2025
Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study.
Journal: Breast (Edinburgh, Scotland)
Published: August 17, 2024
The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
Journal: European review for medical and pharmacological sciences
Published: October 16, 2023
Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy.
Journal: Cancer research and treatment
Published: December 29, 2022
Last Updated: 09/26/2026